REVIEW

Early clearance versus control: what is the meaning of a negative tuberculin skin test or interferon-gamma release assay following exposure to *Mycobacterium tuberculosis*?

[version 1; peer review: 2 approved]

Erin W. Meermeier ¹, David M. Lewinsohn ^{1,2}

¹Pulmonary and Critical Care Medicine, Department of Medicine, Oregon Health and Science University, Portland, USA

²Department of Medicine, VA Portland Health Care System, Portland, OR, USA

V1 First published: 25 May 2018, 7(F1000 Faculty Rev):664
<https://doi.org/10.12688/f1000research.13224.1>
 Latest published: 25 May 2018, 7(F1000 Faculty Rev):664
<https://doi.org/10.12688/f1000research.13224.1>

Abstract

The elimination of tuberculosis (TB) cannot reasonably be achieved by treatment of individual cases and will require an improved vaccine or immunotherapy. A challenge in developing an improved TB vaccine has been the lack of understanding what is needed to generate sterilizing immunity against *Mycobacterium tuberculosis* (Mtb) infection. Several epidemiological observations support the hypothesis that humans can eradicate Mtb following exposure. This has been termed early clearance and is defined as elimination of Mtb infection prior to the development of an adaptive immune response, as measured by a tuberculin skin test or interferon-gamma release assay. Here, we examine research into the likelihood of and possible mechanisms responsible for early clearance in household contacts of patients with active TB. We explore both innate and adaptive immune responses in the lung. Enhanced understanding of these mechanisms could be harnessed for the development of a preventative vaccine or immunotherapy.

Keywords

Mycobacterium tuberculosis, preventative vaccine, infection, household contact studies

Open Peer Review

Approval Status

	1	2
version 1 25 May 2018		

Faculty Reviews are review articles written by the prestigious Members of **Faculty Opinions**. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.

1. **Françoise Mascart**, Université Libre de Bruxelles, Brussels, Belgium
2. **Catherine Stein**, Case Western Reserve University School of Medicine, Wolstein Research Building, Cleveland, USA

Any comments on the article can be found at the end of the article.

Corresponding author: David M. Lewinsohn (lewinsod@ohsu.edu)

Author roles: Meermeier EW: Writing – Original Draft Preparation, Writing – Review & Editing; Lewinsohn DM: Writing – Review & Editing

Competing interests: No competing interests were disclosed.

Grant information: This work was supported by grants from the Bill and Melinda Gates Foundation (to DML), the National Institute of Allergy and Infectious Diseases (R01 AI048090 to DML), the National Heart, Lung, and Blood Institute (T32HL083808 to EWM and DML), and US Department of Veterans Affairs Merit Award #I01 BX000533 from the US Department of Veterans Affairs Biomedical Laboratory Research and Development Program (to DML).

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright: © 2018 Meermeier EW and Lewinsohn DM. This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Meermeier EW and Lewinsohn DM. **Early clearance versus control: what is the meaning of a negative tuberculin skin test or interferon-gamma release assay following exposure to *Mycobacterium tuberculosis*?** [version 1; peer review: 2 approved] F1000Research 2018, 7(F1000 Faculty Rev):664 <https://doi.org/10.12688/f1000research.13224.1>

First published: 25 May 2018, 7(F1000 Faculty Rev):664 <https://doi.org/10.12688/f1000research.13224.1>

Introduction

Tuberculosis (TB) is a leading cause of infectious disease mortality worldwide, accounting for approximately 6.3 million new cases and 1.4 million deaths in 2016 (World Health Organization [WHO] TB Report 2017). The recent emergence of strains of *Mycobacterium tuberculosis* (Mtb) resistant to nearly all effective drug therapy highlights the need for alternative strategies to TB control. The Bacille Calmette–Guérin (BCG) vaccine has been widely used but is controversial, as its efficacy for the prevention of adult TB has been variable. Moreover, despite the widespread use of the BCG vaccine worldwide, the incidence of TB has not dramatically decreased. The elimination of TB cannot reasonably be achieved by treatment of individual cases and will require an improved vaccine or early detection of those likely to progress^{1,2}. The main challenge in developing an improved TB vaccine has been the lack of understanding correlates of protective immunity. What is needed to generate sterilizing immunity against Mtb infection, unlike in many other preventable infectious diseases, is still unknown.

Mtb is transmitted via the aerosol delivery of small particulates into the lung. Here, a dynamic interplay between host immune mechanisms and the virulent bacterium begins with the innate immune system. Innate immunity provides functional and immediate defenses against microbial infection through shared germline-encoded processes and receptors. In addition to the direct recognition and control of microbial infection, innate immunity plays a central role in the initiation and maintenance of subsequent adaptive immune responses. In the lung, Mtb can interact with and infect different cell types, including macrophages, and can establish stable intracellular infection³. When infection overcomes initial physical and immunological defenses,

exposure to pathogen-derived antigens leads to an adaptive immune response over the ensuing two to six weeks. This response relies upon clonal expansion of antigen-specific lymphocytes and forms the basis for immunological memory³. Tuberculin skin tests (TSTs) and interferon-gamma release assays (IGRAs) measure immune sensitization to Mtb and can reflect whether infection has occurred. Individuals who test positively with a TST or IGRA but have no evidence of TB are considered to have latent tuberculosis infection (LTBI). Among LTBI individuals, the estimated lifetime risk of developing TB is roughly 10% (WHO Global TB Report 2016). Neither the TST nor the IGRA can serve as a reflection of bacterial burden⁴. Nonetheless, in the setting of a household exposure, both tests have excellent negative predictive values in that they predict those who are unlikely to get TB^{5,6}.

Upon exposure to Mtb, a number of disparate outcomes can occur. These outcomes include no infection, early clearance of infection, LTBI, and TB (Figure 1). Although about one-quarter of the global population is thought to be infected with Mtb, these epidemiological observations indicate that humans have evolved mechanisms to control or eradicate infection with Mtb. First, some individuals repeatedly exposed to Mtb never demonstrate evidence of immune sensitization by TST or IGRA. These individuals may have been able to eradicate Mtb with an effective innate immune response before an adaptive immune response develops. This phenomenon is termed early clearance. Second, a subset of individuals with a positive TST or IGRA have been observed to revert to a negative result over time⁷. Reversion of these tests may indicate a decrease in bacterial load or clearance of infection and is suggestive of control of Mtb infection. Third, of the individuals considered to have LTBI,

Figure 1. Outcomes of exposure to *Mycobacterium tuberculosis* (Mtb). Mtb exposure can lead to infection, early clearance, latent tuberculosis infection, or, ultimately, tuberculosis. Early clearance occurs before the development of an adaptive immune response detected by a tuberculin skin test (TST) or interferon-gamma release assay (IGRA). Understanding of the underlying mechanisms dictating the outcomes of exposure to Mtb could greatly facilitate the definition of correlates of protective immunity to Mtb infection and generate targets of a preventative vaccine. Possible mechanisms responsible for early clearance in household contacts of active tuberculosis patients that are explored in this review are listed on the right (orange).

most contain infection without developing TB, indicating the development of protective immunity. Although those with LTBI are at risk of reactivation, studies of nursing and medical students in the early twentieth century suggest that a history of infection with *Mtb* correlates with less risk of TB over a lifetime in a subset of individuals. This suggests that prior exposure to *Mtb* could be protective^{8,9}. Evidence to support these three cases of resistance to *Mtb* has been highlighted in two reviews published in 2014^{10,11}. Nevertheless, early clearance of *Mtb* infection has been the focus of intensified research over the past three years. Understanding of these events could greatly facilitate the definition of correlates of protective immunity to *Mtb* infection.

In this commentary review, we present and summarize recent research advances in understanding the epidemiology of early clearance of *Mtb* infection. We include studies of loci of resistance, mechanisms of early clearance, and natural transmission model systems and instigate discussion of the relevance of these advances to vaccines to control infection by *Mtb*.

Evidence for early clearance

A difficulty in studying early clearance of *Mtb* infection has been discerning it from non-exposure, as lack of converting a TST or IGRA could reflect either situation. In the absence of a gold standard for diagnosing *Mtb* infection, it is possible that either test could miss instances of infection. However, given the excellent negative predictive value of both tests, we will consider either negative test as a reflection of resistance to infection^{5,6}. Nevertheless, longitudinal studies of household contacts (HCs) of active TB cases have allowed for the definition of risk factors of *Mtb* infection. For example, a Uganda–Case Western Reserve

University research collaboration has been conducting a long-standing study of HCs since 1995. Recently compiled data from this study were used to define risk factors of *Mtb* infection as measured by TST positivity in over 1,300 individuals. Among adult HCs, there were no significant differences in a multifactorial risk score between individuals who were persistently TST-negative and those who had a positive TST or converted to a positive TST over two years¹². This result was further supported by a culminating analysis of over 2,500 HCs from the same cohort¹³. Here, persistently TST-negative adults did not differ in epidemiologic risk score from other clinical groups. These data suggest that there is still evidence for early clearance even when the degree of exposure is controlled for.

A number of different studies have tried to establish the prevalence of early clearance. Here, the prevalence of early clearance of infection can be defined by a persistent negative TST or IGRA in the setting of *Mtb* exposure. In humans, our best examples of early clearance come from longitudinal (two-plus years) analyses of HCs of TB patients, or those residing in high TB-burden areas, where immune sensitization is carefully monitored. [Table 1](#) and [Table 2](#) summarize longitudinal studies of HCs categorized as persistently TST-negative ([Table 1](#)) or persistently TST- or IGRA-negative or both ([Table 2](#)). As illustrated in [Table 1](#), studies with at least two years of longitudinal observation of HC conversion of TST demonstrated a frequency of early clearance ranging from 3.4%¹⁴ to 26.8%, both in Uganda¹⁵. Whereas the TB Network study that followed HC conversion of IGRA demonstrated that about 58% of exposed HCs lacked evidence of immune sensitization, other studies had a less rigorous definition, as they varied by time of follow-up with individual as well as the likelihood of exposure to TB^{16–20}. Presumably, in some of these studies, higher rates

Table 1. Studies that have determined persistent tuberculin skin test negativity in household contacts.

Location	Duration of observation	Household contacts	Percentage TST-negative	Reference
Uganda ^a	2 years	97	26.8	15
Uganda ^a	2 years	2,585	9.9	21
Tanzania and Uganda	Up to 8 years	469 ^c	48	22
Venezuela ^b	3 years	102 ^d	18.6	23
Uganda ^a	2 years	601	14.5	24
The Gambia ^b	6 months	64	60	20
Uganda ^a	2 years	1,318	11.7	12
Uganda ^a	1–2 years	529	3.4	25
South Africa	None	350	40	14
Pakistan	2 years	93	25	26
Ghana	None	2,346	5.5	19
Uganda ^a	2 years	803	10.5	27

^aSubjects were from the same cohort; ^bnot a high tuberculosis burden area; ^call patients were HIV-positive and only 46% of persons enrolled were household contacts; ^dtuberculosis hospital workers, not household contacts. TST, tuberculin skin test.

Table 2. Studies that have determined persistent interferon-gamma release assay negativity in household contacts.

Location	Duration	Test for <i>Mycobacterium tuberculosis</i> exposure	Household contacts	Percentage IGRA-negative	Reference
Brazil	8–12 weeks	TST and IGRA	838	30.2	16
USA ^a	8–10 weeks	TST and IGRA	569	52	17
Brazil	1 year	TST and IGRA	64	26.5	18
Europe ^a	2 years	IGRA	5,020	58.2	5

^aNot a high tuberculosis burden area. IGRA, interferon-gamma release assay; TST, tuberculin skin test.

of TST- and IGRA-negative HCs could be explained by diminished exposure to Mtb. Nonetheless, extensive epidemiological information collected from the studies in Table 1 and Table 2 suggests that when exposure variables are controlled for, there remains a population of individuals who may be better able to control infection^{12,15,21,24–27}. In this review, we explore possible determinants of early clearance of Mtb infection.

Mechanisms of early clearance of *Mycobacterium tuberculosis* infection

Initial recognition of aerosolized Mtb occurs in the lung, which leads to the production of pro-inflammatory cytokines, chemokines, and antimicrobial peptides (reviewed in 28,29). What determines the outcome of exposure to Mtb? Is infection determined by the virulence of the microbe or more dependent upon host response? Is the immediate response in the respiratory tract important to host protection? Is infection determined by the ability of Mtb to establish a niche in a specific inflammatory microenvironment? Or does the quality, quantity, or organization of lung-resident lymphocytes influence early killing of Mtb and ultimate protection of the host?

I. Early recognition of *Mycobacterium tuberculosis*

The airway is a complex immune organ and likely critical in determining the outcome of Mtb exposure. It exhibits anatomic and functional heterogeneity and contains a diverse array of mechanisms to prevent pulmonary infection, including mucociliary clearance, secreted antibodies, and antimicrobial proteins such as defensins²⁸. Although most research has focused on the alveolus as the initial site of infection, Mtb has ample opportunity to interact with the entire respiratory tract, like other aerosolized particulates. However, how these interactions result in clinically relevant outcomes such as infection and progression to disease is poorly understood. Reuschl *et al.* used polarized human lung epithelial cells in conjunction with myeloid cells to model these early interactions. Following Mtb infection, they mapped global transcriptomic changes in host cells. Interestingly, they found that myeloid cells could license epithelial cells, through interleukin-1 beta (IL-1 β) and type I interferon, resulting in enhanced mycobacterial control³⁰. Additionally, following Mtb infection in the mouse, cathelicidins and related antimicrobial proteins produced by lung macrophages and epithelial cells were required for early clearance of infection³¹. Mounting evidence suggests a role of humoral immunity, including antibodies, and antibody-responsive innate immune cells

bearing Fc-receptors, in protective immunity to Mtb^{32–35}. While studying patients already infected with Mtb, Lu *et al.* explored 70 different antibody features of total serum IgG from patients with LTBI compared with active TB. The authors' data suggested an innate antibody Fc effector profile which led to the restriction of bacterial survival within macrophages³³. When evaluating HCs of patients with active TB, Chin *et al.* observed a different IgA antibody V-gene/D-segment repertoire in those without LTBI compared with those with LTBI, suggesting that a specific type of secretory IgA may promote mucosal protection from Mtb infection³⁶. A recently published genome-wide association study of persistently TST-negative HIV-positive HCs investigated mechanisms of resistance to infection²². Here, HIV-positive contacts who resisted Mtb infection were postulated to have robust innate immunity. Sobota *et al.* found a significant association between TST negativity with a single-nucleotide polymorphism (SNP) at 5q31.1, which is located between *SLC25A48*, a mitochondrial amino acid transporter, and *IL-9*, a cytokine²². *IL-9* has been implicated in bronchial hyperreactivity and as a growth factor for mast cells and T cells²². In an effort to search for biomarkers of stages of Mtb infection, Bark *et al.* evaluated HCs prospectively for differences in serum proteins over two years using mass spectrometry. They compared changes in host proteins in those who were persistently TST- and IGRA-negative, had LTBI, or had TB¹⁵. Tissue integrity proteins, such as keratins, hornerin, lumican, and a component of the extracellular matrix, were more highly expressed in the serum of HCs who did not convert their TST and IGRA. It is interesting to speculate whether these proteins contribute to an essential early barrier against infection. Taken together, these data suggest a distinct role for the respiratory tract as the first line of defense against Mtb infection.

II. Cell-intrinsic mechanisms of host resistance

Mtb virulence is a critical determinant of disease outcome following exposure. Although virulence must be broadly defined, one aspect is certainly the ability of the microbe to circumvent host immunity, such that the outcome reflects this complex interaction. It has been observed that the acquisition of adaptive immunity following infection with Mtb is delayed compared with other infections^{37,38}. As a result, it has been postulated that Mtb has developed immune-evasive mechanisms to orchestrate this delay, allowing unrestricted replication in the lung. In fact, while using a low-dose aerosol model of TB in non-human primates, Gideon *et al.* asked whether there are differences in the immune response upon initial infection that determine the severity of the

outcome³⁹. Through longitudinal blood transcriptome analysis, these data suggested that a highly orchestrated innate and adaptive immune response was crucial for containment of the bacilli.

To determine whether HCs who resist infection or have LTBI differ in their ability to produce innate cytokines in response to Mtb infection, Mahan *et al.* employed a whole blood enzyme-linked immunosorbent assay. Here, the responses to a panel of innate receptor ligands indicated no differences between HCs with or without LTBI²⁵. Although these data imply similar innate immune capabilities between those who remain TST-negative and those with LTBI, the authors state the need for more comprehensive study of innate protective mechanisms. Correspondingly, a subsequent study in HCs from the same district indicated that initial recognition of Mtb by distinct innate receptors contributes to controlling infection. Hall *et al.* performed comparative candidate immune gene SNP analysis in HCs with or without LTBI. They found SNPs in *NOD1*, *NOD2*, *SLC6A3*, *STAT1*, *IL12RB1*, *IL12RB2*, and *TLR4* that associated with a persistently negative TST²⁴. As these are intracellular and extracellular sensors of bacteria, this suggests the need for recognition of infection and activation of the host cell in resistance. Interestingly, NOD2 signaling is increased post-BCG vaccination for up to one year through a phenomenon called trained immunity^{40–42}. Trained immunity is defined as resistance to reinfection and is thought to reflect persistent changes in innate pathways that can lead to memory. Further information from Manzanillo *et al.* supports intracellular sensing; phagosome acidification of Mtb can be triggered through another cytosolic surveillance pathway recognizing microbial cyclic dinucleotides and DNA⁴³. These data indicate that intracellular sensing of Mtb in the host cell is a crucial trigger to controlling the early infection.

A common feature of innate sensing of extracellular and intracellular Mtb is host cell activation, resulting in microbial killing. Host cells can directly kill Mtb by the production of antimicrobial proteins, reactive oxygen species, and acidification of the phagosome^{44,45}. Acidification leads to autophagy, which in turn may help prevent or limit infection. Horne *et al.* found that a human SNP in *ULK1* was associated with infection. CRISPR/Cas9 gene editing to delete *ULK1* revealed that its deficiency in macrophages resulted in augmented Mtb growth, diminished tumor necrosis factor- α (TNF- α) production, and diminished autophagy¹⁷. Other genes associated with the macrophage phagosome, such as *SLC11A1* or *natural resistance-associated macrophage protein 1* (*NRAMP1*), have been linked to the development of TB previously⁴⁶. Although its full function remains to be elucidated, three studies have identified phagosome-associated *NRAMP1* expression as a protein associated with resistance to infection with Mtb. A seminal study of HCs in Uganda²⁷ used a genome-wide linkage analysis to reveal three regions associated with early clearance. Whereas the two most significant regions did not contain characterized genes, a third contained *NRAMP1*. Also, an *NRAMP1* polymorphism in the 3' untranslated region (UTR) was more common in Venezuelan hospital workers who were persistently TST-negative than those with LTBI²³. Additionally, the transcriptome of host cell monocytes derived from persistently TST-negative HCs compared with those with LTBI has been explicitly interrogated by Seshadri *et al.*²¹.

Transcripts associated with histone deacetylase (HDAC) inhibition were enriched among persistently TST-negative HCs. Using chemical inhibition of HDACs in monocytes *in vitro*, the authors observed a role for HDACs in the early immune response to Mtb infection. As HDACs are associated with closed chromatin, this study would support a role for epigenetic programming of host cells in the control of Mtb infection.

Lastly, macrophages capable of non-inflammatory apoptosis and efferocytosis have inherently improved mycobacterial control by limiting intercellular spread⁴⁷. Recent work in animal models of natural transmission supports the hypothesis that augmented apoptosis can result in better control of Mtb infection. In this regard, cows that demonstrate resistance to *Mycobacterium bovis* infection have persistent TST negativity following herd exposure^{48–50}. To explore these mechanisms in cattle, Wu *et al.* generated an *sp110*-TALEN-mediated knock-in cow strain. The gene *Ipr1/sp110* had been previously demonstrated to be associated with innate immunity to TB in mice⁵¹. Sp110 is a nuclear body that permits apoptosis over inflammatory cell death in infected macrophages which decreases the viability of Mtb and limits intercellular spread⁵². In a breakthrough finding, transgenic cattle where murine *sp110* is selectively expressed in macrophages were more resistant to *M. bovis* infection when a cow with active TB was placed in a herd⁵³. Macrophages from transgenic cattle were better able to “restrain” intracellular Mtb and preferentially died by apoptosis over necrosis *in vitro*. Although nitric oxide (NO) is traditionally thought to play a direct role in TB control, it is also shown to limit granulocytic inflammation and tissue damage in the context of Mtb infection, in part through modification of the inflammasome⁵⁴. Subsequently, it is interesting that Mtb-infected macrophages from TST-negative cattle were recently shown to produce more NO⁵⁰. Therefore, NO, a molecule made in abundance in human lung epithelial cells, has additional functions that may contribute to preventing infection with Mtb. These studies advocate that non-inflammatory cell death and innate antimicrobial responses derived from genetics or trained epigenetics of the host cell can contribute to controlling Mtb infection.

III. Unconventional lymphocytes coordinate early lung inflammation to limit *Mycobacterium tuberculosis* infection

Longitudinal case control studies (Table 1 and Table 2) would indicate that infection by Mtb can be controlled without an adaptive T-cell response^{18,20,25,55–58}. In addition to macrophages, lymphocytes, especially T cells, could orchestrate this response to Mtb infection. In addition to antigen-specific HLA-I and HLA-II restricted cells that can be reflected in a TST and IGRA, a variety of cells are capable of recognizing the Mtb-infected cell that may not be reflected in these assays. First, it is possible that a TST or IGRA test fails to reflect lung-resident memory T cells that do not circulate systemically^{59,60}. Specifically, it has been argued that classically restricted tissue-resident memory T cells may recognize Mtb-infected cells and confer protection before the acquisition of a peripheral adaptive immune response^{61–63}. Second, unconventional T cells, including CD1-restricted cells, MR1-restricted mucosal-associated invariant T (MAIT) cells, HLA-E/Qa-1-restricted cells, and $\gamma\delta$ T cells, can also recognize

Mtb infection and are poised at mucosal sites such as the lung⁵⁹. Each of these cell populations can also kill infected host cells through cytotoxic granules and produce cytokines in the context of Mtb. Mouse models of TB have been used to decipher whether these subsets have a protective role in the antimicrobial immune response. Using mice deficient in the antigen-presentation element, researchers have observed a role for MR1-restricted MAIT cells and Qa-1-restricted cells in the early response to Mtb infection^{64–66}. In parallel experiments, group I CD1-restricted T cells specific to Mtb-derived lipids conferred protection in human CD1-transgenic mice^{67,68}. Mouse models of TB do not suggest a non-redundant role for natural killer T cells or $\gamma\delta$ T cells in a chronic TB setting, although they do show changes in frequency and phenotype in association with human Mtb infection^{69,70}. Moreover, group-I CD1-, HLA-E-, and MR1-restricted T cells specific to Mtb antigen have been detected in individuals with active or LTBI infection^{68,71–75}. Collectively, these studies indicate a strong possibility that lung-resident T-cell populations play a role in the early immune response to Mtb in humans.

Lastly, natural transmission models of Mtb infection in guinea pigs have provided us with an important example of sterilizing adaptive immunity. Guinea pigs demonstrate a range of susceptibility to Mtb infection in natural transmission experiments^{76,77}. A unique set-up of these experiments includes the direct exposure of guinea pigs to air from patients. They reflect many features of human immunity such as variable progression to disease. Additionally, some guinea pigs displayed the early clearance phenotype in that they became infected and then reverted to a negative TST. Sterilizing immunity was supported by the observation that the animals did not have granulomas or cultivable mycobacteria, and conversion was prevented by irradiating the air. Furthermore, administration of dexamethasone did not result in TB. As the prevalence of sterilizing immunity in humans is uncertain, future lessons from model systems may provide a paradigm of immune memory that may be crafted into future vaccine strategy or immune therapeutics.

The immune race to control *Mycobacterium tuberculosis* infection

Viewed in aggregate, the studies presented here illustrate immune mechanisms that may facilitate early clearance or the

eradication of Mtb before an adaptive immune response develops. In humans, our best indicators of early clearance come from longitudinal (two-plus years) analyses of HCs of TB patients or those residing in high TB burden areas, where exposure to Mtb and immune sensitization are carefully monitored. It is important to recognize that much of our knowledge of the host-defense mechanisms comes from the study of those with chronic disease. However, studies focusing on the early acute phases of Mtb infection have provided insights that support early and successful lung-resident immunity as key for preventing infection. As TB eradication will depend on preventing transmission, understanding immune correlates, such as improved macrophage function, mucosal antibodies, or enhanced recognition of the infected cell, will present new opportunities to prevent Mtb infection.

Abbreviations

BCG, Bacille Calmette–Guérin; HC, household contact; HDAC, histone deacetylase; HLA, human leukocyte antigen; IGRA, interferon-gamma release assay; IL, interleukin; LTBI, latent tuberculosis infection; MAIT, mucosal-associated invariant T; Mtb, *Mycobacterium tuberculosis*; NO, nitric oxide; NRAMP1, natural resistance-associated macrophage protein 1; SNP, single-nucleotide polymorphism; TB, tuberculosis; TST, tuberculin skin test; WHO, World Health Organization

Competing interests

The authors declare that they have no competing interests.

Grant information

This work was supported by grants from the Bill and Melinda Gates Foundation (to DML), the National Institute of Allergy and Infectious Diseases (R01 AI048090 to DML), the National Heart, Lung, and Blood Institute (T32HL083808 to EWM and DML), and US Department of Veterans Affairs Merit Award #H01 BX000533 from the US Department of Veterans Affairs Biomedical Laboratory Research and Development Program (to DML).

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

1. Dye C, Glaziou P, Floyd K, *et al.*: **Prospects for tuberculosis elimination.** *Annu Rev Public Health.* 2013; **34**: 271–86.
[PubMed Abstract](#) | [Publisher Full Text](#)
2. Abu-Raddad LJ, Sabatelli L, Achterberg JT, *et al.*: **Epidemiological benefits of more-effective tuberculosis vaccines, drugs, and diagnostics.** *Proc Natl Acad Sci U S A.* 2009; **106**(33): 13980–5.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
3. O'Garra A, Redford PS, McNab FW, *et al.*: **The immune response in tuberculosis.** *Annu Rev Immunol.* 2013; **31**: 475–527.
[PubMed Abstract](#) | [Publisher Full Text](#)
4. Pai M, Denkinger CM, Kik SV, *et al.*: **Gamma interferon release assays for detection of *Mycobacterium tuberculosis* infection.** *Clin Microbiol Rev.* 2014; **27**(1): 3–20.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
5. Zellweger JP, Sotgiu G, Block M, *et al.*: **Risk Assessment of Tuberculosis in Contacts by IFN- γ Release Assays. A Tuberculosis Network European Trials Group Study.** *Am J Respir Crit Care Med.* 2015; **191**(10): 1176–84.
[PubMed Abstract](#) | [Publisher Full Text](#)
6. Rieder HL, Cauthen GM, Comstock GW, *et al.*: **Epidemiology of tuberculosis in the United States.** *Epidemiol Rev.* 1989; **11**: 79–98.
[PubMed Abstract](#) | [Publisher Full Text](#)

7. Nardell EA, Wallis RS: **Here today—gone tomorrow: the case for transient acute tuberculosis infection.** *Am J Respir Crit Care Med.* 2006; **174**(7): 734–5.
[PubMed Abstract](#) | [Publisher Full Text](#)
8. Andrews JR, Noubary F, Walensky RP, *et al.*: **Risk of progression to active tuberculosis following reinfection with *Mycobacterium tuberculosis*.** *Clin Infect Dis.* 2012; **54**(6): 784–91.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
9. Esmail H, Barry CE 3rd, Young DB, *et al.*: **The ongoing challenge of latent tuberculosis.** *Philos Trans R Soc Lond B Biol Sci.* 2014; **369**(1645): 20130437.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
10. Verrall AJ, Netea MG, Alisjahbana B, *et al.*: **Early clearance of *Mycobacterium tuberculosis*: a new frontier in prevention.** *Immunology.* 2014; **141**(4): 506–13.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
11. Hawn TR, Day TA, Scriba TJ, *et al.*: **Tuberculosis vaccines and prevention of infection.** *Microbiol Mol Biol Rev.* 2014; **78**(4): 650–71.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
12. Ma N, Zalwango S, Malone LL, *et al.*: **Clinical and epidemiological characteristics of individuals resistant to *M. tuberculosis* infection in a longitudinal TB household contact study in Kampala, Uganda.** *BMC Infect Dis.* 2014; **14**: 352.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
13. **F** Stein CM, Zalwango S, Malone LL, *et al.*: **Resistance and Susceptibility to *Mycobacterium Tuberculosis* Infection and Disease in Tuberculosis Households in Kampala, Uganda.** *Am J Epidemiol.* 2018.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
14. Cobat A, Gallant CJ, Simkin L, *et al.*: **Two loci control tuberculin skin test reactivity in an area hyperendemic for tuberculosis.** *J Exp Med.* 2009; **206**(12): 2583–91.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
15. **F** Bark CM, Manceur AM, Malone LL, *et al.*: **Identification of Host Proteins Predictive of Early Stage *Mycobacterium tuberculosis* Infection.** *EBioMedicine.* 2017; **21**: 150–7.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
16. Jones-López EC, Acuña-Villaorduña C, Fregona G, *et al.*: **Incident *Mycobacterium tuberculosis* infection in household contacts of infectious tuberculosis patients in Brazil.** *BMC Infect Dis.* 2017; **17**(1): 576.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
17. Horne DJ, Graustein AD, Shah JA, *et al.*: **Human ULK1 Variation and Susceptibility to *Mycobacterium tuberculosis* Infection.** *J Infect Dis.* 2016; **214**(8): 1260–7.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
18. Araujo LS, da Silva NBM, da Silva RJ, *et al.*: **Profile of interferon-gamma response to latency-associated and novel *in vivo* expressed antigens in a cohort of subjects recently exposed to *Mycobacterium tuberculosis*.** *Tuberculosis (Edinb).* 2015; **95**(6): 751–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
19. Thyte T, Browne EN, Chinbuah MA, *et al.*: **IL10 haplotype associated with tuberculin skin test response but not with pulmonary TB.** *PLoS One.* 2009; **4**(5): e5420.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
20. Buchwald UK, Adetifa IM, Bottomley C, *et al.*: **Broad adaptive immune responses to *M. tuberculosis* antigens precede TST conversion in tuberculosis exposed household contacts in a TB-endemic setting.** *PLoS One.* 2014; **9**(12): e116268.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
21. **F** Seshadri C, Sedaghat N, Campo M, *et al.*: **Transcriptional networks are associated with resistance to *Mycobacterium tuberculosis* infection.** *PLoS One.* 2017; **12**(4): e0175844.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
22. Fletcher HA, Snowden MA, Landry B, *et al.*: **T-cell activation is an immune correlate of risk in BCG vaccinated infants** *Nat Commun.* 2016; **7**: 11290.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
23. Li HT, Zhang TT, Zhou YQ, *et al.*: **SLC11A1 (formerly *NRAMP1*) gene polymorphisms and tuberculosis susceptibility: a meta-analysis.** *Int J Tuberc Lung Dis.* 2006; **10**(1): 3–12.
[PubMed Abstract](#)
24. Hall NB, Igo RP Jr, Malone LL, *et al.*: **Polymorphisms in *TICAM2* and *IL1B* are associated with TB.** *Genes Immun.* 2015; **16**(2): 127–33.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
25. Mahan CS, Zalwango S, Thiel BA, *et al.*: **Innate and adaptive immune responses during acute *M. tuberculosis* infection in adult household contacts in Kampala, Uganda.** *Am J Trop Med Hyg.* 2012; **86**(4): 690–7.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
26. Hussain R, Talat N, Shahid F, *et al.*: **Biomarker changes associated with Tuberculin Skin Test (TST) conversion: a two-year longitudinal follow-up study in exposed household contacts.** *PLoS One.* 2009; **4**(10): e7444.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
27. **F** Stein CM, Zalwango S, Malone LL, *et al.*: **Genome scan of *M. tuberculosis* infection and disease in Ugandans.** *PLoS One.* 2008; **3**(12): e4094.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
28. **F** Sobota RS, Stein CM, Kodaman N, *et al.*: **A chromosome 5q31.1 locus associates with tuberculin skin test reactivity in HIV-positive individuals from tuberculosis hyper-endemic regions in east Africa.** *PLoS Genet.* 2017; **13**(6): e1006710.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
29. Fernández-Mestre M, Villasmil Á, Takiff H, *et al.*: ***NRAMP1* and *VDR* Gene Polymorphisms in Susceptibility to Tuberculosis in Venezuelan Population.** *Dis Markers.* 2015; **2015**: 860628.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
30. Parker D, Prince A: **Innate immunity in the respiratory epithelium.** *Am J Respir Cell Mol Biol.* 2011; **45**(2): 189–201.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
31. Li W, Deng G, Li M, *et al.*: **Roles of Mucosal Immunity against *Mycobacterium tuberculosis* Infection.** *Tuberc Res Treat.* 2012; **2012**: 791728.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
32. **F** Reuschl AK, Edwards MR, Parker R, *et al.*: **Innate activation of human primary epithelial cells broadens the host response to *Mycobacterium tuberculosis* in the airways.** *PLoS Pathog.* 2017; **13**(9): e1006577.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
33. **F** Gupta S, Winglee K, Gallo R, *et al.*: **Bacterial subversion of cAMP signalling inhibits cathelicidin expression, which is required for innate resistance to *Mycobacterium tuberculosis*.** *J Pathol.* 2017; **242**(1): 52–61.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
34. Torrado E, Fountain JJ, Robinson RT, *et al.*: **Differential and site specific impact of B cells in the protective immune response to *Mycobacterium tuberculosis* in the mouse.** *PLoS One.* 2013; **8**(4): e61681.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
35. **F** Lu LL, Chung AW, Rosebrock TR, *et al.*: **A Functional Role for Antibodies in Tuberculosis.** *Cell.* 2016; **167**(2): 433–443.e14.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
36. Phuah JY, Mattila JT, Lin PL, *et al.*: **Activated B cells in the granulomas of nonhuman primates infected with *Mycobacterium tuberculosis*.** *Am J Pathol.* 2012; **181**(2): 508–14.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
37. Chin ST, Ignatius J, Suraiya S, *et al.*: **Comparative study of IgA V_H 3 gene usage in healthy TST and TST+ population exposed to tuberculosis: deep sequencing analysis.** *Immunology.* 2015; **144**(2): 302–11.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
38. WALLGREN A: **The time-table of tuberculosis.** *Tubercle.* 1948; **29**(11): 245–51.
[PubMed Abstract](#) | [Publisher Full Text](#)
39. Chackerian AA, Alt JM, Perera TV, *et al.*: **Dissemination of *Mycobacterium tuberculosis* is influenced by host factors and precedes the initiation of T-cell immunity.** *Infect Immun.* 2002; **70**(8): 4501–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
40. **F** Gideon HP, Skinner JA, Baldwin N, *et al.*: **Early Whole Blood Transcriptional Signatures Are Associated with Severity of Lung Inflammation in Cynomolgus Macaques with *Mycobacterium tuberculosis* Infection.** *J Immunol.* 2016; **197**(12): 4817–28.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
41. Kleinnijenhuis J, Quintin J, Preijers F, *et al.*: **Bacille Calmette-Guérin induces NOD2-dependent nonspecific protection from reinfection via epigenetic reprogramming of monocytes.** *Proc Natl Acad Sci U S A.* 2012; **109**(43): 17537–42.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
42. **F** Arts RJW, Carvalho A, La Rocca C, *et al.*: **Immunometabolic Pathways in BCG-Induced Trained Immunity.** *Cell Rep.* 2016; **17**(10): 2562–71.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
43. Kleinnijenhuis J, Quintin J, Preijers F, *et al.*: **Long-lasting effects of BCG vaccination on both heterologous Th1/Th17 responses and innate trained immunity.** *J Innate Immun.* 2014; **6**(2): 152–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
44. **F** Manzanillo PS, Shiloh MU, Portnoy DA, *et al.*: ***Mycobacterium tuberculosis* activates the DNA-dependent cytosolic surveillance pathway within macrophages.** *Cell Host Microbe.* 2012; **11**(5): 469–80.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
45. **F** Gutierrez MG, Master SS, Singh SB, *et al.*: **Autophagy is a defense mechanism inhibiting BCG and *Mycobacterium tuberculosis* survival in infected macrophages.** *Cell.* 2004; **119**(6): 753–66.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
46. Deretic V, Delgado M, Vergne I, *et al.*: **Autophagy in immunity against *mycobacterium tuberculosis*: a model system to dissect immunological roles of autophagy.** *Curr Top Microbiol Immunol.* 2009; **335**: 169–88.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
47. Martin CJ, Peters KN, Behar SM: **Macrophages clean up: efferocytosis and microbial control.** *Curr Opin Microbiol.* 2014; **17**: 17–23.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
48. Barthel R, Piedrahita JA, McMurray DN, *et al.*: **Pathologic findings and association of *Mycobacterium bovis* infection with the bovine *NRAMP1* gene in cattle from herds with naturally occurring tuberculosis.** *Am J Vet Res.* 2000; **61**(9): 1140–4.
[PubMed Abstract](#) | [Publisher Full Text](#)
49. Khatri BL, Coad M, Clifford DJ, *et al.*: **A natural-transmission model of bovine tuberculosis provides novel disease insights.** *Vet Rec.* 2012; **171**(18): 448.
[PubMed Abstract](#) | [Publisher Full Text](#)
50. **F** Alcaraz-López OA, García-Gil C, Morales-Martínez C, *et al.*: **Divergent**

- macrophage responses to *Mycobacterium bovis* among naturally exposed uninfected and infected cattle. *Immunol Cell Biol.* 2017; 95(5): 436–42.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
51. **F** Pan H, Yan BS, Rojas M, *et al.*: *Ipr1* gene mediates innate immunity to tuberculosis. *Nature.* 2005; 434(7034): 767–72.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 52. **F** Wu Y, Guo Z, Yao K, *et al.*: The Transcriptional Foundations of Sp110-mediated Macrophage (RAW264.7) Resistance to *Mycobacterium tuberculosis* H37Ra. *Sci Rep.* 2016; 6: 22041.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 53. **F** Wu H, Wang Y, Zhang Y, *et al.*: TALE nickase-mediated SP110 knockin endows cattle with increased resistance to tuberculosis. *Proc Natl Acad Sci U S A.* 2015; 112(13): E1530–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 54. **F** Mishra BB, Lovewell RR, Olive AJ, *et al.*: Nitric oxide prevents a pathogen-permissive granulocytic inflammation during tuberculosis. *Nat Microbiol.* 2017; 2: 17072.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 55. García Jacobo RE, Serrano CJ, Enciso Moreno JA, *et al.*: Analysis of Th1, Th17 and regulatory T cells in tuberculosis case contacts. *Cell Immunol.* 2014; 289(1–2): 167–73.
[PubMed Abstract](#) | [Publisher Full Text](#)
 56. Riaño F, Arroyo L, París S, *et al.*: T cell responses to DosR and Rpf proteins in actively and latently infected individuals from Colombia. *Tuberculosis (Edinb).* 2012; 92(2): 148–59.
[PubMed Abstract](#) | [Publisher Full Text](#)
 57. Hesselink AC, Mandalakas AM, Kirchner HL, *et al.*: Highly discordant T cell responses in individuals with recent exposure to household tuberculosis. *Thorax.* 2009; 64(10): 840–6.
[PubMed Abstract](#) | [Publisher Full Text](#)
 58. Leyten EM, Lin MY, Franken KL, *et al.*: Human T-cell responses to 25 novel antigens encoded by genes of the dormancy regulon of *Mycobacterium tuberculosis*. *Microbes Infect.* 2006; 8(8): 2052–60.
[PubMed Abstract](#) | [Publisher Full Text](#)
 59. **F** Godfrey DI, Uldrich AP, McCluskey J, *et al.*: The burgeoning family of unconventional T cells. *Nat Immunol.* 2015; 16(11): 1114–23.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 60. Masopust D, Picker LJ: Hidden memories: frontline memory T cells and early pathogen interception. *J Immunol.* 2012; 188(12): 5811–7.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 61. Beverley PC, Sridhar S, Lalvani A, *et al.*: Harnessing local and systemic immunity for vaccines against tuberculosis. *Mucosal Immunol.* 2014; 7(1): 20–6.
[PubMed Abstract](#) | [Publisher Full Text](#)
 62. Horvath CN, Shaler CR, Jeyanathan M, *et al.*: Mechanisms of delayed anti-tuberculosis protection in the lung of parenteral BCG-vaccinated hosts: a critical role of airway luminal T cells. *Mucosal Immunol.* 2012; 5(4): 420–31.
[PubMed Abstract](#) | [Publisher Full Text](#)
 63. Jeyanathan M, Heriazon A, Xing Z: Airway luminal T cells: a newcomer on the stage of TB vaccination strategies. *Trends Immunol.* 2010; 31(7): 247–52.
[PubMed Abstract](#) | [Publisher Full Text](#)
 64. Sakala IG, Kjer-Nielsen L, Eickhoff CS, *et al.*: Functional Heterogeneity and Antimycobacterial Effects of Mouse Mucosal-Associated Invariant T Cells Specific for Riboflavin Metabolites. *J Immunol.* 2015; 195(2): 587–601.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 65. Chua WJ, Truscott SM, Eickhoff CS, *et al.*: Polyclonal mucosa-associated invariant T cells have unique innate functions in bacterial infection. *Infect Immun.* 2012; 80(9): 3256–67.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 66. **F** Bian Y, Shang S, Siddiqui S, *et al.*: MHC Ib molecule Qa-1 presents *Mycobacterium tuberculosis* peptide antigens to CD8⁺ T cells and contributes to protection against infection. *PLoS Pathog.* 2017; 13(5): e1006384.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 67. **F** Felio K, Nguyen H, Dascher CC, *et al.*: CD1-restricted adaptive immune responses to *Mycobacteria* in human group 1 CD1 transgenic mice. *J Exp Med.* 2009; 206(11): 2497–509.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 68. **F** Zhao J, Siddiqui S, Shang S, *et al.*: Mycolic acid-specific T cells protect against *Mycobacterium tuberculosis* infection in a humanized transgenic mouse model. *eLife.* 2015; 4: pii: e08525.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 69. Arora P, Foster EL, Porcelli SA: CD1d and natural killer T cells in immunity to *Mycobacterium tuberculosis*. *Adv Exp Med Biol.* 2013; 783: 199–223.
[PubMed Abstract](#) | [Publisher Full Text](#)
 70. Chen ZW: Multifunctional immune responses of HMBPP-specific V γ 2V δ 2 T cells in *M. tuberculosis* and other infections. *Cell Mol Immunol.* 2013; 10(1): 58–64.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 71. Joosten SA, van Meijgaarden KE, van Weeren PC, *et al.*: *Mycobacterium tuberculosis* peptides presented by HLA-E molecules are targets for human CD8 T-cells with cytotoxic as well as regulatory activity. *PLoS Pathog.* 2010; 6(2): e1000782.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 72. Lewinsohn DM, Briden AL, Reed SG, *et al.*: *Mycobacterium tuberculosis*-reactive CD8⁺ T lymphocytes: the relative contribution of classical versus nonclassical HLA restriction. *J Immunol.* 2000; 165(2): 925–30.
[PubMed Abstract](#) | [Publisher Full Text](#)
 73. **F** Kasmar AG, van Rhijn I, Cheng TY, *et al.*: CD1b tetramers bind $\alpha\beta$ T cell receptors to identify a mycobacterial glycolipid-reactive T cell repertoire in humans. *J Exp Med.* 2011; 208(9): 1741–7.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 74. Montamat-Sicotte DJ, Millington KA, Willcox CR, *et al.*: A mycolic acid-specific CD1-restricted T cell population contributes to acute and memory immune responses in human tuberculosis infection. *J Clin Invest.* 2011; 121(6): 2493–503.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 75. **F** Gold MC, Cerri S, Smyk-Pearson S, *et al.*: Human mucosal associated invariant T cells detect bacterially infected cells. *PLoS Biol.* 2010; 8(6): e1000407.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 76. Riley RL, Mills CC, Nyka W, *et al.*: Aerial dissemination of pulmonary tuberculosis. A two-year study of contagion in a tuberculosis ward. 1959. *Am J Epidemiol.* 1995; 142(1): 3–14.
[PubMed Abstract](#) | [Publisher Full Text](#)
 77. Dharmadhikari AS, Basaraba RJ, Van Der Walt ML, *et al.*: Natural infection of guinea pigs exposed to patients with highly drug-resistant tuberculosis. *Tuberculosis (Edinb).* 2011; 91(4): 329–38.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

Open Peer Review

Current Peer Review Status:

Editorial Note on the Review Process

Faculty Reviews are review articles written by the prestigious Members of **Faculty Opinions**. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.

The reviewers who approved this article are:

Version 1

1. Catherine Stein

Department of Population and Quantitative Health Sciences, Case Western Reserve University School of Medicine, Wolstein Research Building, Cleveland, OH, USA

Competing Interests: No competing interests were disclosed.

2. Françoise Mascart

Laboratory of Vaccinology and Mucosal Immunology, Université Libre de Bruxelles, Brussels, Belgium

Competing Interests: No competing interests were disclosed.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research